Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.29), FiscalAI reports. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $2.27 million.
Here are the key takeaways from Inovio Pharmaceuticals’ conference call:
- Inovio received FDA accelerated approval for VOCERYQ, its first commercial product and the first FDA-approved plasmid DNA-based immunotherapy, for adults with recurrent respiratory papillomatosis (RRP). In the FDA’s analysis of 26 patients with at least three prior-year surgeries, 27% required no surgery in the 12 months after treatment; the company also cited durable responses and a generally favorable tolerability profile.
- Inovio is preparing a U.S. launch, with product availability expected about 60 days after approval and full field deployment targeted for Q1 2027. Management estimates at least 25,000 adult RRP patients in the U.S. and says its planned field team is designed to reach 90% of patient potential, though payer coverage and uptake estimates are based on company research.
- VOCERYQ’s accelerated approval requires a confirmatory study to verify clinical benefit, and continued approval may depend on its results. Inovio plans to submit a draft protocol by year-end and aims to agree on a final design with the FDA by mid-2027; the study is expected to include at least 50 adult and pediatric patients.
- After an equity offering that generated about $80.5 million in net proceeds, plus quarter-end cash and subsequent warrant exercises, Inovio expects to fund operations into late Q4 2027, excluding potential VOCERYQ revenue or future fundraising. The company reported Q3 operating expenses of $19.8 million, down from $21.2 million a year earlier; its $49.2 million net loss was primarily driven by a non-cash warrant fair-value adjustment.
Inovio Pharmaceuticals Stock Down 4.0%
Shares of NASDAQ INO traded down $0.06 during midday trading on Tuesday, reaching $1.45. 14,207,659 shares of the company were exchanged, compared to its average volume of 4,845,135. The stock’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.27. The stock has a market cap of $149.93 million, a P/E ratio of -1.59 and a beta of 1.71. Inovio Pharmaceuticals has a one year low of $0.56 and a one year high of $2.72.
Wall Street Analyst Weigh In
Several research analysts have commented on INO shares. Jefferies Financial Group restated a “buy” rating and set a $8.00 price objective (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday. Zacks Research cut Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. Weiss Ratings downgraded Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. HC Wainwright set a $5.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.67.
Read Our Latest Stock Analysis on Inovio Pharmaceuticals
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.
Further Reading
- Five stocks we like better than Inovio Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
